India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India-focused Independent Equity Research Analyst

Experienced (7 years +) in Sector-Specific Deep Dives and Comprehensive Company Research.

With a sharp focus on the Indian market, I specialize in providing in-depth analysis and insights to investors. Whether it's dissecting various sectors to identify emerging trends or conducting thorough fundamental research on individual companies, I'm dedicated to uncovering valuable opportunities and delivering actionable intelligence.

Passionate about navigating the nuances of the Indian equity landscape, I thrive on deciphering complex market dynamics and distilling them into clear, concise insights. 

While covering a sector or company-specific research, I cover the following :
1. Brief about company/sector
2.  Overall Industry landscape - History, Present and Future trends
3. Thesis and Anti-Thesis
4. Valuations
5. Financial & Forensic Analysis
6. Management Review
7. Key Monitorable Events
8. Guidance and Future Way Ahead

India Equity Analyst - Fundamental & Thematic

The Beat Ideas: Narayana Hrudayalaya Ltd (NHL) ~ Driving Growth from India to Cayman Islands

The Beat Ideas: Adani Cements:  Massive 140 MTPA Capacity Expansion, A Roadmap to FY28

The Beat Ideas: Innova Captab Ltd, Jammu Capex Kicker, Margin Expansion

The Beat Ideas: Blue Jet Healthcare- Rising CDMO Player

The Beat Ideas: Sigachi Industries- High Growth, Revenue Diversification, New Category Launch

The Beat Ideas: Globus Spirits- Maize, Capex, B2C Play

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

Solara Active Pharma Sciences / Equity Bottom-Up

Solara Active Pharma Sciences (SOLARA IN)

<ul>
<li>Refocusing on the core business with the promoter stepping back on the board &amp; demerger. Also focusing on value-added products and reducing debt from rights issues &amp; internal accruals.</li>
<li>
<a href="https://www.smartkarma.com/entities/solara-active-pharma-sciences" target="_blank" data-smartkarma-citation="entities:33800:1" rel="noopener">Solara Active Pharma Sciences (SOLARA IN)</a> had issues in getting US FDA approvals for the Visakhapatnam facility &amp; pricing pressure on the key product Ibuprofen.</li>
<li>The CRAMS and high-potent API segments have the potential to generate significant value over the next 4-5 years through the addition of new customers.</li>
</ul>


Refocusing on the core business with the promoter stepping back on the board &amp; demerger. Also focusing on value-added products and reducing debt from rights issues &amp; internal accruals.

Solara Active Pharma Sciences (SOLARA IN) had issues in getting US FDA approvals for the Visakhapatnam facility &amp; pricing pressure on the key product Ibuprofen.
The CRAMS and high-potent API segments have the potential to generate significant value over the next 4-5 years through the addition of new customers.


The Beat Ideas: Solara Active Pharma Science~ Turnaround & Value Unlocking Via Demerger